Research programme: cardiovascular disease therapeutic - Daewoong Pharmaceutical
Alternative Names: IMD5; Incrementally modified drug 5Latest Information Update: 16 Jul 2016
At a glance
- Originator Daewoong Pharmaceutical
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Atherosclerosis; Hyperlipidaemia
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Atherosclerosis in South Korea
- 16 Jul 2016 No recent reports of development identified for research development in Hyperlipidaemia in South Korea
- 25 Feb 2011 Early research in Hyperlipidaemia in South Korea (unspecified route)